Patau syndrome > patau syndrome diagnosis > Ninalia NIPT

NIPT by Biomnis The new prenatal trisomy screening test based on maternal blood sample

Trisomy 13

Download the brochure

Patau Syndrome

To Rule Out Patau Syndrome Risks, Choose Non-Invasive Prenatal Screening

When deciding whether traditional prenatal screening for fetal chromosomal abnormalities including Patau Syndrome (trisomy 13) is worth the potential complications, it can be difficult to weigh the options and risks. Luckily, there are now safe and easy-to-administer alternatives to amniocentesis that offer close to 100% accurate detection of Patau Syndrome and related disorders, including Down Syndrome and Edwards's Syndrome. The ground-breaking, entirely non-invasive prenatal screening kit developed by Eurofins Biomnis is a simple genetic test for pregnant women at risk of trisomy 13, 18, and 21. The NIPT tests quickly and effectively detect all three of these common fetal complications, and offer expectant parents peace of mind, early on.

Available starting from only the tenth week of pregnancy, theEurofins Biomnis Patau Syndrome diagnosis kit offers effective non-invasive genetic testing during pregnancy, detecting risks for Trisomy 13 and related chromosomal abnormalities. With a rate of accuracy nearing 100%, the test is performed by drawing a simple maternal blood sample. Aside from maternal DNA, maternal blood contains fetal DNA originating from the placenta. The identification of fetal DNA in this sample, in tandem with a new technology capable of counting all genetic material sequences within it, allows for an accurate detection of abnormalities. Opting for an NIPT Patau Syndromediagnosismay allow you to limit or entirely forgo invasive screening procedures.

While patients may assume that Patau Syndrome prenatal diagnosis is necessarily a complicated medical procedure, Eurofins Biomnis has developed non-invasive types of prenatal screening that are remarkably simple to prescribe and administer. The NIPT kits are prescribed by your healthcare provider; the test can either be administered by your physician or by aEurofinsBiomnis partner laboratory. Screening can take place early in your pregnancy, after 10 weeks of pregnancy. With results of the blood test generally available within 7 working days, NIPT by Eurofins Biomnis is an efficient, safe, and remarkably accurate way to undergo Patau Syndrome prenatal diagnosis. It has been found to reduce unnecessary invasive sampling by up to 95%.

Advantages of NIPT by Biomnis

> 99 % Detection rateof NIPT test 1 Single blood sample 10 Available from week 10of amenorrhoea 7 Results availablewithin 7 working days 95 % Can minimize unnecessary invasive sampling by 95%